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Real-time monitoring of the spatial and temporal progression of infection/gene expression in animals will
contribute greatly to our understanding of host-pathogen interactions while reducing the number of animals
required to generate statistically significant data sets. Sensitive in vivo imaging technologies can detect low
levels of light emitted from luciferase reporters in vivo, but the existing reporters are not optimal for fungal
infections. Therefore, our aim was to develop a novel reporter system for imaging Candida albicans infections
that overcomes the limitations of current luciferase reporters for this major fungal pathogen. This luciferase
reporter was constructed by fusing a synthetic, codon-optimized version of the Gaussia princeps luciferase gene
to C. albicans PGA59, which encodes a glycosylphosphatidylinositol-linked cell wall protein. Luciferase ex-
pressed from this PGA59-gLUC fusion (referred to as gLUC59) was localized at the C. albicans cell surface,
allowing the detection of luciferase in intact cells. The analysis of fusions to strong (ACT1 and EFT3), oxidative
stress-induced (TRX1, TRR1, and IPF9996), and morphogenesis-dependent (HWP1) promoters confirmed that
gLUC59 is a convenient and sensitive reporter for studies of gene regulation in yeast or hyphal cells, as well
as a flexible screening tool. Moreover, the ACT1-gLUC59 fusion represented a powerful tool for the imaging of
disease progression in superficial and subcutaneous C. albicans infections. gLUC59 and related cell surface-
exposed luciferase reporters might find wide applications in molecular biology, cell biology, pathobiology, and
high-throughput screens.
Candida albicans is responsible for a large fraction of fungal
infections in humans (5) and, as such, has received consider-
able attention from the research community over the last two
decades. C. albicans now represents an invaluable model for
dissecting the interplay between fungal pathogens and their
hosts at the molecular level (31, 32, 43, 45, 50). Studies of
host-pathogen interactions have been greatly facilitated by the
use of ex vivo infection models where isolated microorganisms
and host cells or reconstituted tissues are brought into contact
and the kinetics of pathogen and host cell responses are mon-
itored (12, 14, 23, 36, 45). Yet, animal models remain necessary
complements to ex vivo infection models, because none of
these models fully reflect the development of clinical infec-
tions. Animal models allow researchers to monitor the behav-
ior of mutant microorganisms or the expression of reporter
genes in the complex environments of organs and in the pres-
ence of a fully functional or debilitated immune system (3,
20, 24).
A current limitation of animal models is the need to
sacrifice animals in order to image microorganisms at the
site of infection. In particular, studies aimed at evaluating
whether conditions known to trigger the expression of a
specific C. albicans gene in vitro are encountered at sites of
infection have often relied on the detection of a reporter in
tissue sections. Several reporter genes are available for gene
expression studies of C. albicans, such as the Streptococcus
thermophilus -galactosidase lacZ gene (46) and the sea
pansy (Renilla reniliformis) luciferase gene (41), but most in
vivo studies have taken advantage of derivatives of the Ae-
quorea victoria green fluorescent protein (GFP) gene, whose
product can be detected primarily through its natural fluo-
rescence but also through immunochemistry in tissue sec-
tions (2, 7, 16, 28). In particular, GFP fusions have been
used to examine the niche-specific expression of central
metabolic pathways and oxidative stress responses in C.
albicans during disease progression (3, 10).
As the detection of GFP (and of other reporters such as
-galactosidase) is possible only in tissue sections, it is not
possible to monitor in real time the spatial and temporal pro-
gression of C. albicans infection/gene expression in a single
animal. Real-time monitoring would represent a significant
advance because it would probably reveal meaningful varia-
tions in fungus/host responses that can be masked by the het-
erogeneous behavior of individual animals (24). Real-time
monitoring might also reveal the spread of C. albicans to un-
expected infection sites. Furthermore, real-time monitoring
would reduce the number of animals required to generate
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statistically significant data sets (19). In this regard, in recent
years in vivo imaging technologies have been developed that
take advantage of sensitive charge-coupled device cameras to
detect low levels of light emitted from luciferase reporters in
vivo. Pioneering work by Contag et al. (6) demonstrated that
bioluminescent Salmonella could be localized to specific tissues
in live animals, allowing the temporal monitoring of the infec-
tion process and of the efficacy of antimicrobial treatment. This
approach has now been extended to numerous pathogenic
bacteria, virus, and parasites (19), and several luciferases are
available for in vivo imaging, including firefly luciferase (fLUC
from Photinus pyralis), which catalyzes light production from
luciferin and ATP, and sea pansy luciferase (rLUC) and Gaus-
sia princeps luciferase (gLUC), which catalyze light production
from coelenterazine in an ATP-independent manner (37, 44,
47). Recently, Doyle et al. (8, 9) showed that light emitted by
C. albicans strains expressing the firefly luciferase gene under
the control of the strong C. albicans ENO1 promoter could be
detected in animals with induced vulvovaginal candidiasis that
had been subjected to a vaginal lavage with a solution contain-
ing luciferin. The efficacy of an antifungal treatment could be
monitored over a period of 19 days through imaging of the
same group of animals. However, this in vivo reporter system
did not allow detection of C. albicans during systemic candidi-
asis. As pointed out by those authors, their failure to detect
light in animals despite efficient kidney colonization by lumi-
nescent C. albicans might have resulted from the limited per-
meability of hyphal cells to luciferin and the attenuation of
light emitted from the kidneys by overlying tissues (8). Fur-
thermore, the inability to detect intracellular firefly luciferase
in hyphal cells represents a major limitation for further studies
of C. albicans, since the yeast-to-hypha transition is a major
virulence determinant in this species (35).
In the present study, we have successfully circumvented most
of these limitations by engineering a luciferase that becomes
exposed at the cell surface and hence is readily accessible to its
substrate whether C. albicans is in the yeast or hyphal form.
This was achieved by fusing a synthetic, codon-optimized ver-
sion of the gene for the naturally secreted Gaussia princeps
luciferase (44) to the C. albicans PGA59 gene, which encodes
a glycosylphosphatidylinositol (GPI)-linked cell wall protein
required for cell wall integrity (27). We confirm that the
PGA59-gLUC gene fusion (referred to as gLUC59) is a conve-
nient and powerful reporter for in vitro gene expression studies
using intact yeast or hyphal C. albicans cells. Moreover, we
show that bioluminescence imaging is a powerful tool for the
detailed monitoring of the spatiotemporal behavior of cutane-
ous, subcutaneous, and vaginal C. albicans infections in live
animals. The gLUC59 reporter is also useful for the analysis of
systemic infections, although the uneven distribution of the G.
princeps luciferase substrate, coelenterazine, in live animals
prevents accurate quantitative analysis of such infections.
MATERIALS AND METHODS
Strains, media, and growth conditions. All C. albicans strains used in this study
are listed in Table 1. Strains were routinely grown at 30°C on YPD medium (1%
yeast extract, 2% peptone, 2% glucose) or SD minimal medium (0.67% yeast
nitrogen base without amino acids, 2% glucose, pH 5.4) supplemented with
uridine (40 to 80 g/ml), arginine (20 to 50 g/ml), and histidine (20 g/ml) (38).
RPMI 1640 (Gibco) medium or YPD plus 10% fetal bovine serum was used to
induce hyphal formation in liquid culture. RPMI 1640 medium was buffered with
50 mM HEPES, pH 7.3. To impose stress upon C. albicans, cells were first grown
at 30°C for 48 h in SD to saturation and were then diluted to an optical density
at 600 nm of 0.2 in fresh YPD and incubated at 37°C for 4 to 5 h with shaking.
H2O2 (final concentrations of 0.1 mM to 30 mM), S-nitrosoglutathione (0.2 mM
to 2 mM), and NaCl (0.3 M to 1 M) were added to induce oxidative, nitrosative,
and osmotic stress, respectively. Heat stress was performed by transferring mid-
exponential cultures from 25°C to 37°C or 42°C.
Plasmids and construction of C. albicans strains. All oligonucleotides used in
this study are listed in Table 2. The lithium acetate procedure used to transform
C. albicans has been described previously (48).
The BamHI-PflMI fragment of pGEM-T::(PGA59-GFP, ARG4) carrying the
GFP open reading frame (27) was replaced by a BamHI-PflMI fragment carrying
the G. princeps luciferase gene (44) that was optimized for expression in C.
albicans using the subset of preferred codons for this organism (4, 22, 34) and
synthesized by GeneArt (Regensburg, Germany), yielding plasmid pGEM-T::
(PGA59-gLUC, ARG4). Strains CEC749 and CEC751 were obtained through
TABLE 1. Candida albicans strains used in this study
Strain Parent Genotype Reference
CAI4 ura3::imm434/ura3::imm434 11
SM22 CAI8 ura3::imm434/ura3::imm434 ade2::hisG/ADE2-ACT1p-RLUC This study
BWP17 ura3::imm434/ura3::imm434 arg4::hisG/arg4::hisG his1::hisG/his1::hisG 49
CEC175 BWP17 ura3::imm434/URA3 arg4::hisG/arg4::hisG his1::hisG/his1::hisG 15
CEC161 BWP17 ura3::imm434/ura3::imm434 ARG4/arg4::hisG HIS1/his1::hisG This study
CEC749 BWP17U ura3::imm434/URA3 arg4::hisG/arg4::hisG his1::hisG/his1::hisG PGA59/(PGA59-gLUC)-
ARG4-PGA59
This study
CEC751 BWP17U ura3::imm434/URA3 arg4::hisG/arg4::hisG his1::hisG/his1::hisG PGA59/(PGA59-GFP)-
ARG4-PGA59
This study
CA1399 CAI4 ura3::imm434/ura3::imm434 RPS10/RPS10::CIp10-PGA59-gLUC This study
CA1398 CAI4 ura3::imm434/ura3::imm434 RPS10/RPS10::CIp10-ACT1p-PGA59-gLUC This study
CA1435 CAI4 ura3::imm434/ura3::imm434 RPS10/RPS10::CIp10-TRR1p-PGA59-gLUC This study
CA1400 CAI4 ura3::imm434/ura3::imm434 RPS10/RPS10::CIp10-TRX1p-PGA59-gLUC This study
CA1434 CAI4 ura3::imm434/ura3::imm434 RPS10/RPS10::CIp10-IPF9996p-PGA59-gLUC This study
CEC987 CEC161 ura3::imm434/ura3::imm434 ARG4/arg4::hisG HIS1/his1::hisG RPS10/RPS10::CIp10-
ACT1p-PGA59-gLUC
This study
CEC971 CEC161 ura3::imm434/ura3::imm434 ARG4/arg4::hisG HIS1/his1::hisG RPS10/RPS10::CIp10-
HWP1p-PGA59-gLUC
This study
CEC975 CEC161 ura3::imm434/ura3::imm434 ARG4/arg4::hisG HIS1/his1::hisG RPS10/RPS10::CIp10-
EFT3p-PGA59-gLUC
This study
CEC369 CEC161 ura3::imm434/ura3::imm434 ARG4/arg4::hisG HIS1/his1::hisG RPS10/RPS10::CIp10 This study
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transformation of C. albicans strain CEC175 using SnaBI-linearized pGEM-T::
(PGA59-gLUC, ARG4) and pGEM-T::(PGA59-GFP, ARG4), respectively.
CIp10::ACT1p-yEGFP is a derivative of the integrative CIp10 plasmid (29)
that carries the yeast enhanced GFP gene (yEGFP) (7) downstream of a 1,024-bp
fragment carrying the 5 noncoding region of the C. albicans ACT1 gene (2). The
1,440-bp PGA59-gLUC fragment was amplified from pGEM-T::(PGA59-gLUC,
ARG4) using oligonucleotides Enj_LUC_HindIII_5 and Enj_LUC_NheI_3
(Table 2) and subcloned at the HindIII and NheI sites in CIp10::ACT1p-yEGFP
in place of yEGFP to yield CIp10::ACT1p-gLUC59 (Fig. 1). The promoter re-
gions for TRR1 (970 bp of the 5 region upstream of the start codon), TRX1 (975
bp), IPF9996 (978 bp), HWP1 (2,023 bp), and EFT3 (1,556 bp) were amplified
from C. albicans genomic DNA using oligonucleotides listed in Table 2 and
subcloned at the XhoI and HindIII sites in place of the ACT1 promoter to yield
CIp10::TRR1p-gLUC59, CIp10::TRX1p-gLUC59, CIp10::IPF9996p-gLUC59,
CIp10::HWP1p-gLUC59, CIp10::TEC1p-gLUC59, and CIp10::EFT3p-gLUC59,
respectively. These CIp10 derivatives were linearized with StuI, integrated at the
C. albicans RPS1 locus, and proper integration was confirmed by PCR and/or
Southern analysis (data not shown).
Luciferase assays. C. albicans cells grown in liquid culture were collected by
centrifugation and washed twice in luciferase assay buffer (LA buffer) (0.5 M
NaCl, 0.1 M K2HPO4 [pH 6.7], 1 mM EDTA, 0.6 mM NaN3, 1 mM phenyl-
methylsulfonyl fluoride cocktail [Boehringer]). Coelenterazine (Molecular
Probes, Eugene, OR) in LA buffer was added to a final concentration of 1.25
M, and luciferase activity was recorded using a luminometer.
To assay C. albicans cells in microtiter plate format, a dilution series was
prepared for each culture, and 100 l of each dilution was deposited in black
transparent-well microtiter plates and mixed with 100 l of 2 M coelenterazine
in LA buffer. The microtiter plate was immediately placed on top of X-ray film
for 2 min. Signal intensities obtained after autoradiography were quantified with
AIDA 2.0 software (Raytest, Straubenhardt, Germany) to estimate the luciferase
activity.
C. albicans colonies growing on YPD plates were replicated onto 3 M filter
papers. One milliliter of LA buffer containing 1.25 M coelenterazine was then
deposited on the filter paper. The filter paper was wrapped in saran film and
exposed to X-ray film (Kodak) for 5 min.
Antifungal susceptibility testing. Susceptibility testing was performed by the
M27-A microdilution method of the National Committee for Clinical Laboratory
Standards in 0.165 M MOPS (morpholinepropanesulfonic acid)-buffered RPMI
1640 (pH 7). After 18 h of incubation of growth of a gLUC59-expressing Candida
albicans strain (CEC987 [Table 1]) in the presence or absence of econazole (1
g/ml) or amphotericin B (1 g/ml), 10 g/ml of coelenterazine substrate was
added and samples were read using a luminometer (Tecan).
Antimicrobial activity of neutrophils. Heparinized venous blood from healthy
donors was diluted with RPMI 1640, and white blood cells were separated by
Ficoll-Hypaque density gradient centrifugation. The pellet containing neutro-
phils (PMNs) and erythrocytes was treated with hypotonic saline to lyse the
erythrocytes. PMNs were collected by centrifugation, washed, counted, and re-
suspended in RPMI 1640 plus 10% fetal calf serum. Killing activity was evaluated
by CFU inhibition assay and by luciferase activity of gLUC59 Candida albicans.
A total of 105 PMNs were incubated in 96-well microtiter tissue culture plates
with 104 yeast cells for 2 h. After incubation at 37°C, plates were vigorously
shaken, cells were lysed by addition of 0.01% Triton X-100, 10 g/ml of coelen-
terazine was added to each sample, and plates were read using a luminometer.
After the reading, samples were diluted in distilled water, and cell lysates were
plated for CFU on Sabouraud dextrose agar.
Animal models of infection and imaging. Seven-week-old CD1 female mice
(Harlan, Milan, Italy) were housed in groups of four mice per cage. All C.
albicans strains were grown on YPD agar and subcultured in YPD medium at
room temperature for 16 h. Cells were harvested, washed twice in sterile endo-
toxin-free physiological saline, counted with a hemocytometer, and adjusted to
the final concentration (see below) in sterile physiological saline.
The mouse model of cutaneous infection has been described previously (13).
Mice were immunosuppressed with cyclophosphamide 3 days prior to infection
(150 mg  kg1), the day of the infection (150 mg  kg1), and 3 days postinfec-
tion (50 mg  kg1). On the day of the infection, mice were anesthesized with 80
l of pentobarbital (50 mg  kg1) and shaved over an area of 4 cm2 until all fur
was removed, and the skin was abraded with sandpaper until it was glistening.
Twenty microliters of a 5  108  ml1 C. albicans cell suspension was deposited
on the abraded area. In selected experiments, econazole or amphotericin B
(Sigma) was administered intraperitoneally once daily postinfection at a dose of
10 mg  kg1 of body weight. Infection was monitored at 1, 2, 3, 4, and 7 days
postinfection by depositing 20 l coelenterazine (500 g  ml1 in 1:9 methanol-
phosphate-buffered saline [PBS]; Synchem OHG, Felsberg/Altemburg) on the
abraded skin area and imaging the animals dorsal side up in an IVIS-200 imaging
system (Xenogen Corporation, Alameda, CA) under anesthesia with 2.5% isoflu-
rane.
For subcutaneous infection, mice were inoculated subcutaneously in the right
thigh region with 100 l of a 108  ml1 C. albicans cell suspension. After
challenge and every day postinfection, mice were injected subcutaneously with
TABLE 2. Oligonucleotides used in this study
Oligonucleotide Sequence (533)a
Enj_LUC_HindIII_5 .............................................................GCAGAAGCTTTATTAAAATGATGCAATTCTCATCCGCTATTATCTTATCTGC
Enj_LUC_NheI_3..................................................................CGCCGCTAGCGCGGGATCAGGAGAAACAAAGATGTATAAGG
TTR1_Xho1_5 .......................................................................ATATCTCGAGAACGGTGAGAAAGATCGTGGATTTGGTC
TTR1_HindIII_3....................................................................ATATAAGCTTCAAAAGAAAGAAAGAAAAGAAAAAAAAGGGGC
TRX1_Xho1_5 .......................................................................ATATCTCGAGATGTACTTGAGGAGTAAAGTATAGAAAAACAG
TRX1_HindIII_3 ...................................................................ATATAAGCTTCTTTGAAAAAAAATATAACTATGTGTTAAGTG
IPF9996_Xho1_5 ...................................................................ATATCTCGAGAACACTTGGACCTACACTCAGATCCCAAAC
IPF9996_HindIII_3 ...............................................................ATATAAGCTTCCTCTAGCTTGATTAAGAACTTGAAAAATTTGG
HWP1_XhoI_5.......................................................................CGGCTCGAGAACCAAAGAGTAAAAACTTG
HWP1_Hind III_3 .................................................................CCTGAAGCTTCATATTGACGAAACTAAAAGCG
EFT3_XhoI_5 ........................................................................CGGCTCGAGTTATTACTAACATATAC
EFT3_Hind III_3...................................................................CCTGAAGCTTCATTTTCCAAAATGTTG
a Underlining indicates HindIII, NheI, or XhoI restriction site.
FIG. 1. Schematic representation of the Cip10::ACT1p-gLUC59
vector. The CIp10::ACT1p-gLUC59 vector is a derivative of the C.
albicans CIp10 integrative vector (29), which harbors the C. albicans
URA3 transformation marker and which, upon cleavage by StuI, inte-
grates at the C. albicans RPS1 locus. A XhoI/HindIII fragment encom-
passing the ACT1 promoter (ACT1p) was cloned upstream of the
gLUC59 luciferase reporter gene. gLUC59 is a fusion between the C.
albicans PGA59 gene and the Gaussia princeps luciferase gene (gLUC).
Propagation of CIp10::ACT1p-gLUC59 is achieved in Escherichia coli
in the presence of ampicillin (bla).
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100 l coelenterazine (500 g  ml1 in 1:9 methanol-PBS) and imaged as
described above. In selected experiments, granuloma was removed histologically
and then analyzed or homogenized, the fungal burden was determined in YPD
agar plus chloramphenicol, and then CFU were evaluated.
The mouse model of vaginal infection has been described previously (8). Five
days prior to infection a pseudo-estrus condition was induced in mice by subcu-
taneous injection of 0.2 mg estradiol valerate in 100 l sesame oil (Sigma). This
was repeated weekly until the completion of the study. Mice anesthetized with
2.5 to 3.0% (vol/vol) isoflurane gas were infected twice at a 24-h interval with 10
l of a 109  ml1 C. albicans cell suspension administered from a mechanical
pipette into the vaginal lumen, close to the cervix. To favor vaginal contact and
adsorption of fungal cells, mice were held head down for 1 min following
inoculation. Mice were then allowed to recover for 24 to 48 h, during which the
Candida infection was established. Every day postinfection, 10 l (1 mg  ml1 in
1:4 methanol-PBS) of coelenterazine was added to the vaginal lumen. After-
wards, mice were imaged as described above. In selected experiments, mice were
anesthetized with 2.5% isoflurane and then held head down, the vaginal lumen
was thoroughly washed with 50 l of saline, and the lavage fluid was monitored
with the IVIS-200 system. To determine the fungal load in the vagina, the lavage
solution from each mouse was serially diluted and plated on YPD agar plus
chloramphenicol, and then CFU were evaluated.
The mouse model of systemic candidiasis has been previously described (33).
Mice were inoculated by injection of a 200-l yeast suspension into the lateral
tail vein (final amount, 2.5 105 CFU per mouse) through a 27-gauge needle. At
regular time intervals, mice were injected intraperitoneally with 200 l coelen-
terazine (500 g  ml1 in 1:9 methanol-PBS) and imaged dorsal side up in the
IVIS-200 imaging system. After the final imaging point, mice were injected with
200 l coelenterazine (500 g/ml in 1:9 methanol-PBS), humanely sacrificed, and
autopsied in order to image organs using the IVIS-200 imaging system.
Total photon emission from selected and defined areas within the images of
each mouse was quantified with the Living Image software package.
Nucleotide sequence accession number. The nucleotide sequence of the
PGA59-gLUC gene fusion has been deposited at the NCBI under accession
number FJ790493.
RESULTS
Intracellular Renilla reniliformis luciferase is not accessible
to its substrate coelenterazine. The rLUC gene has been used
extensively as a reporter of gene expression in C. albicans (1,
17, 21, 41). However, experiments using rLUC have been car-
ried out using whole-cell extracts for in vitro quantification of
luciferase activity. Because in vivo imaging of luciferase activity
requires that the substrate must be accessible to the luciferase,
we tested whether light could be detected from intact C. albi-
cans cells expressing intracellular rLUC. As shown in Fig. 2A,
intact C. albicans cells of strain SM22 expressing the rLUC
gene under the control of the strong C. albicans ACT1 pro-
moter displayed a luciferase activity of 0.025 relative light units
(RLU)/cell, while whole-cell extracts from the same culture
displayed a 50-fold-higher luciferase activity. These data sug-
gested that coelenterazine could not penetrate C. albicans cells
efficiently and that luciferases that use coelenterazine as a
substrate could not be exploited for in vivo imaging if localized
intracellularly.
Development of a novel reporter gene that drives cell sur-
face localization of the Gaussia princeps luciferase in C. albi-
cans. The data presented above and those obtained by Doyle et
al. (9) suggested that neither luciferin nor coelenterazine could
penetrate C. albicans cells efficiently. Therefore, we reasoned
that the successful development of a luciferase reporter suit-
able for in vivo imaging would depend upon the exposure of
this luciferase at the C. albicans cell surface. For this purpose,
a codon-optimized version of the gLUC gene was cloned in
frame within the C. albicans PGA59 gene between the codons
for the second and third amino acids of the mature Pga59
protein, thereby placing the synthetic gLUC coding region
downstream of the Pga59 signal sequence (Fig. 1). The gLUC
luciferase gene was selected over other possible luciferase
genes because it encodes a naturally secreted luciferase that is
small (185 amino acids) and that does not require ATP for
activity (44). During codon optimization we selected those
codons that are preferentially used in C. albicans, and we
avoided the use of CTG codons, which are translated as serine
instead of leucine in C. albicans (4, 22, 34). C. albicans PGA59
was selected to target gLUC to the C. albicans surface because
it encodes a short (113-amino-acid) GPI-linked cell wall pro-
tein that has been used previously to efficiently target GFP to
the C. albicans cell wall (27). When the resulting PGA59-gLUC
construct was integrated at the PGA59 locus of C. albicans
strain BWP17U, high luciferase activities were detected from
intact exponentially growing cells (3.11 RLU/cell) (Fig. 2B),
and similar luciferase levels were detected from whole-cell
extracts (2.60 RLU/cell) (Fig. 2B). Luciferase was also de-
tected in the culture supernatant, although at much lower
levels (data not shown). In contrast, control C. albicans cells
containing a PGA59-GFP fusion integrated at the PGA59 locus
did not show any significant luciferase activity from intact
(0.54  103 RLU/cell) or lysed (0.58  103 RLU/cell) cells
(Fig. 2B).
The construction reported above was obtained by fusing the
gLUC gene at the junction between the second and third
codons of the PGA59 gene. This resulted in a fusion protein
where the signal peptides of Pga59 and gLUC are in tandem
upstream of the gLUC and Pga59 domains. Additional
PGA59-gLUC gene fusions were constructed where either the
gLUC signal peptide or the main Pga59 domain was omitted.
The omission of the gLUC signal peptide resulted in C. albi-
cans strains with no detectable luciferase activity, while omis-
sion of the main Pga59 domain resulted in C. albicans strains
with much lower luciferase activity than with the original
PGA59-gLUC fusion (data not shown). The expression of the
codon-optimized gLUC gene alone, without appended PGA59
sequences, resulted in the secretion of luciferase by the C.
albicans cells into the culture supernatant in a manner that was
dependent upon the gLUC signal peptide (data not shown). As
our aim was to develop a reporter gene where the luciferase
remains associated with cells and does not diffuse through the
animal body following release from C. albicans cells, we fo-
cused our further studies on the original PGA59-gLUC gene
fusion that included the signal peptides of both Pga59 and
gLUC and that is referred below as gLUC59 (Fig. 1).
This gLUC59 reporter gene was subcloned into CIp10, a C.
albicans integrative plasmid (29) downstream of the C. albicans
ACT1 promoter to generate an ACT1p-gLUC59 gene fusion
(Fig. 1). When the resulting plasmid was integrated at the
RPS1 locus in C. albicans strain CAI4, a strong luciferase
activity (757 RLU/cell) (Fig. 2A) was detected from intact
exponentially growing (data not shown) or stationary-phase
cells, and high luciferase activity levels were detected from
whole-cell extracts (323 RLU/cell) (Fig. 2A). The luciferase
activity detected from intact cells was at least 104-fold higher
than that detected from C. albicans strains expressing rLUC
under the control of the ACT1 promoter, and whole-cell ex-
tracts of the gLUC59-expressing strain had about 300 times
more luciferase activity than those of the corresponding rLUC-
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expressing strain (Fig. 2A). Indeed, light could be detected
using a luminometer from as few as a thousand gLUC59-
expressing cells (Fig. 2C). Strikingly, light could even be de-
tected by the naked eye when a culture of the gLUC59 ex-
pressing strain was incubated with coelenterazine in darkness
(Fig. 2D). Moreover, colonies of the gLUC59-expressing strain
could be detected by autoradiography when overlaid with co-
elenterazine (Fig. 2E).
FIG. 2. Cell surface G. princeps luciferase (gLUC59) is a highly sensitive reporter of gene expression in C. albicans. (A) C. albicans cells expressing
the R. reniliformis luciferase gene (rLUC) or a fusion between the C. albicans PGA59 gene and the G. princeps luciferase gene (PGA59-gLUC) expressed
under the control of the C. albicans ACT1 promoter (ACT1p) were grown in YPD medium at 30°C. Luciferase activity was measured using intact cells
(black bar) or whole-cell extracts (white bar) and coelenterazine as substrate. Error bars indicate standard deviations. (B) C. albicans cells expressing
fusions between the C. albicans PGA59 gene and the A. victoria GFP gene (PGA59-GFP) or the G. princeps luciferase gene (PGA59-gLUC) expressed
under the control of the C. albicans PGA59 promoter (PGA59p) were grown in YPD medium at 30°C. Luciferase activity was measured using intact cells
(black bar) or whole-cell extracts (white bar) and coelenterazine as substrate. (C) Increasing numbers of C. albicans ACT1p-gLUC59 cells grown in YPD
medium at 30°C were incubated in LA buffer. Luciferase activity was measured using intact cells with coelenterazine as substrate. (D) Coelenterazine was
added to a culture in YPD (at 30°C) of a C. albicans strain expressing the gLUC59 reporter under the control of the ACT1 promoter, and pictures were
taken using a standard camera in the light or darkness. (E) C. albicans ACT1p-gLUC59 (ACT1) or control cells were grown on agar plates and replicated
on filter papers. The papers were soaked in a solution containing coelenterazine and autoradiographed. Images show a superimposition of these
autoradiographs upon pictures of the corresponding plates.
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We conclude that C. albicans Pga59 can be used to efficiently
target gLUC to the C. albicans cell surface and that the Pga59-
gLUC protein is accessible to its substrate.
gLUC59 is a convenient reporter for gene expression studies
in vitro. The use of firefly luciferase as a reporter for in vivo
imaging is in part limited by the poor diffusion of luciferin
through the cell wall and membrane of C. albicans hyphae (8,
9). Therefore, we tested whether gLUC59 activity could be
detected on intact C. albicans hyphae as well as yeast cells. C.
albicans strain CA1398 expressing gLUC59 under the control
of the ACT1 promoter was grown for 3 hours in YPD at 30°C
(yeast phase) and in YPD at 37°C in the absence or presence
of 10% fetal bovine serum (hyphal phase), and gLUC59 activ-
ity was measured. As shown in Fig. 3A, gLUC59 activity was
detected on intact yeast and hyphal cells. Therefore, gLUC59
can serve as a reporter for gene expression irrespective of the
morphological state of C. albicans.
In order to test whether gLUC59 could be used as a reporter
of gene expression under a variety of conditions, a set of
gLUC59 promoter fusions were constructed and integrated at
the C. albicans RPS1 locus. These fusions carried the promot-
ers from the TRX1, TRR1, IPF9996, HWP1, and EFT3 genes
upstream of gLUC59 (Table 1). TRX1, TRR1, and IPF9996
encode a thioredoxin, a thioredoxin reductase, and a protein of
unknown function, respectively, and their expression has been
shown to be upregulated in response to oxidative stress (10).
HWP1 encodes a GPI-linked cell wall protein that is specifi-
cally expressed in hyphal cells (42). EFT3 encodes translation
elongation factor 3 and is upregulated in some infection mod-
els (23, 30, 50).
As shown in Fig. 3A, the expression of the TRX1p-gLUC59
fusion increased as the concentration of hydrogen peroxide
was raised to 5 mM. Above this concentration, gLUC59 levels
decreased. In contrast, gLUC59 levels remained unchanged
when the cells expressing this TRX1p-gLUC59 fusion were
exposed to nitrosative or heat stress or induced to undergo the
yeast-to-hypha transition (Fig. 3A). Similar data were obtained
using a C. albicans strain expressing the TRR1p-gLUC59 fusion
(data not shown). Moreover, no significant increase in cell
surface luciferase activity was observed when a C. albicans
strain carrying the ACT1p-gLUC59 fusion was exposed to ox-
idative stress. Therefore, the luciferase levels detected in intact
C. albicans cells expressing TRX1p-gLUC59 or TRR1p-gLUC59
fusions accurately reflected our published observation that the
C. albicans TRX1 and TRR1 genes are induced specifically in
response to oxidative stress (10). A similar regulatory profile
was observed for the IPF9996p-gLUC59 fusion, although this
gene was expressed at lower levels than the TRX1 fusion (Fig.
3A). Again this was consistent with our previous observation
that IPF9996 is expressed at relatively low levels. Indeed, in our
hands the IPF9996 promoter was not sufficiently active to drive
GFP expression at detectable levels (B. Enjalbert and A. J. P.
Brown, unpublished data). However, in this study IPF9996p-
gLUC59 expression levels were orders of magnitude above the
limit of detection.
Morphogenesis was induced in cells carrying the ACT1p-
gLUC59, EFT3p-gLUC59, and HWP1p-gLUC59 fusions in
RPMI medium at 37°C, and luciferase activities were recorded
at different time intervals (Fig. 3B). While EFT3p-gLUC59
expression levels remained relatively constant over the course
of the experiment, the HWP1p-gLUC59 fusion was strongly
upregulated in response to hyphal induction, as expected (42).
These data indicated that, unlike the fLUC reporter (8),
gLUC59 can be used to monitor the expression of hypha-
induced genes under hypha-inducing conditions.
Taken together, these data showed that gLUC59 is an ex-
ceptionally sensitive reporter that can be used to monitor the
expression of diverse C. albicans promoters under a variety of
experimental conditions without the need to prepare C. albi-
cans cell lysates.
gLUC59 is a convenient reporter of cell viability. Prior to
conducting animal experiments using a C. albicans gLUC59-
expressing strain, we tested whether killing or growth inhibi-
tion of such cells by antifungals or PMNs resulted in changes in
luciferase activity. Growth of C. albicans strain CA1398 carry-
ing the ACT1p-gLUC59 fusion in the presence of econazole (1
g/ml) or amphotericin B (1 g/ml) reduced luciferase activity
by 82% or 99%, respectively (data not shown). Moreover,
killing of C. albicans CA1398 cells by PMNs was associated
with a decrease in luciferase activity that correlated strongly
with cell counts (Fig. 4). Therefore, gLUC59 provided a re-
porter of viable C. albicans cells.
gLUC59 can be used to monitor the progression of superfi-
cial C. albicans infections in live animals. We then tested
whether gLUC59 could be used to monitor the course of dif-
ferent types of C. albicans infection. Mice were infected with C.
albicans strain CA1398 carrying the ACT1p-gLUC59 fusion
(gLUC59 strain below) or the control strain CA1399, which did
not express gLUC59. Preliminary studies showed that these
gLUC59 and control strains were equally pathogenic in the
mouse model of systemic infection (data not shown).
Different experimental infections were used, such as subcu-
taneous, cutaneous, vaginal, and systemic infections. Subcuta-
neous inoculation was performed in the right thigh region
through injection of 107 gLUC59 or control cells, and these
infections were imaged at various time points over a 1-week
period (see Materials and Methods). Figure 5A and B show
representative examples of images and luminescence data ob-
tained for an uninfected mouse, a mouse infected with
gLUC59, and a mouse infected with the control strain. For the
gLUC59 strain a progressive increase in luminescence was
observed from day 1 to 5 postinfection, and this observation
was reproducible (n  5). This signal was higher than those
obtained with mice infected with the control strain or with
uninfected mice. The luminescence signals observed for mice
infected with the gLUC59 strain decreased at days 6 and 7
postinfection but remained higher than those observed for the
control mice. A typical granuloma started to develop at the site
of inoculation at 1 day postinfection. Histological analyses
revealed the presence of a cellular infiltrate composed pre-
dominantly of neutrophils, macrophages, some lymphocytes,
and yeast and hyphal cells (data not shown). C. albicans cells
were quantified in a CFU assay, showing that the fungal bur-
dens increased between the first and fourth days of infection
and subsequently decreased (Fig. 5C), consistent with the lu-
ciferase detection in live animals.
Cutaneous infections (13) were examined in immunosup-
pressed mice using 107 gLUC59 or control cells. After 1 day of
infection, selected groups of mice were treated intraperitone-
ally with econazole or amphotericin B (once daily for 4 days),
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and the infections were imaged at various time points. Figure
6 shows a representative example of the images obtained for
four mice infected with control or gLUC59 cells and treated
with econazole or amphotericin B. Strong gLUC59 signals
were maintained for over 1 week in the untreated mice in-
fected with the gLUC59 strain. In contrast, these signals dis-
appeared rapidly in mice treated with econazole or amphoter-
icin B (Fig. 6). As expected, no significant signals were
FIG. 3. gLUC59 is a convenient reporter for gene expression studies in vitro. (A) C. albicans strains expressing ACT1p-gLUC59, TRX1p-
gLUC59, or IPF9996p-gLUC59 fusions were grown under a range of conditions and luciferase activities recorded using intact cells: yeast cells in
YPD at 30°C (Y-H 30°C), hyphal cells in YPD at 37°C (Y-H 37°C), hyphal cells in YPD containing 10% serum at 37°C (Y-H 37°CS), control
and heat-shocked yeast cells in YPD (25°C-25°C, 25°C-37°C, 25°C-42°C), yeast cells subjected to nitrosative stress (S-nitrosoglutathione [GSNO],
0 to 2 mM), and yeast cells subjected to oxidative stress (H2O2, 0 to 30 mM). Insets show the morphology of C. albicans cells expressing the
ACT1p-gLUC59 reporter when grown under yeast- or hypha-inducing conditions. Note that different scales are used for the IPF9996p-gLUC59
strain compared with the other strains. Error bars indicate standard deviations. (B) C. albicans strains expressing ACT1p-gLUC59, EFT3p-gLUC59,
and HWP1p-gLUC59 fusions were grown in RPMI medium, and luciferase activities were recorded using intact cells at different time points.
Luciferase activities for cells expressing the EFT3p-gLUC59 and HWP1p-gLUC59 fusions were normalized to those for ACT1p-gLUC59 cells under
equivalent conditions to correct for time-dependent increases in culture density.
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observed in mice infected with the control strain. These obser-
vations confirm that the gLUC59 reporter can be used to
examine the impact of antifungal drugs upon these infections.
Next we examined the utility of the gLUC59 reporter for
vaginal infections (8). Significant luminescence signals were
evident at 4 to 6 days postinfection for mice infected with
the gLUC59 strain, and these signals declined by day 8
postinfection (Fig. 7A). In contrast, only weak luminescence
was observed for mice infected by the control strain (Fig.
7A). In selected experiments a vaginal wash was performed
on the infected mice, and luminescence in the recovered
fluid was assayed. Strong luminescence was observed in va-
ginal fluids obtained from gLUC59-infected mice, whereas
no significant signal was seen in mice infected with the
control strain (Fig. 7B and C). Fungal burdens in these
vaginal fluids were also determined and confirmed that the
luminescence signal correlated strongly with the presence of
C. albicans cells (Fig. 7C).
Taken together, these data showed that the gLUC59 re-
porter can be used to image cutaneous, subcutaneous, and
vaginal C. albicans infections and the impact of antifungal
treatments.
Applicability of gLUC59 for monitoring C. albicans systemic
infections. To test whether gLUC59 could be used to monitor
the spread of C. albicans during the progression of systemic
infections (33), mice were injected via the tail vein with C.
FIG. 4. gLUC59 is a convenient reporter of cell viability. C.
albicans ACT1p-gLUC59 (CA1398) cells were incubated in the pres-
ence of three independent preparations of PMNs for 2 h at 37°C.
Luciferase activity and CFU were subsequently recorded and were
highly correlated (r  0.975). Error bars indicate standard devia-
tions.
FIG. 5. In vivo imaging of mice injected subcutaneously with Candida albicans ACT1p-gLUC59. Mice were inoculated subcutaneously in the
right thigh region with 107 ACT1p-gLUC59 (CA1398) or control (CA1399) cells. On days 1, 4, 5, 6, and 7 postinfection, mice were injected at the
same site with 50 g of coelenterazine and imaged in the IVIS-200 imaging system under anesthesia with 2.5% isoflurane. (A) Representative
images of untreated mice and mice infected with ACT1p-gLUC59 or control strains. (B) Histogram of the means and standard deviations of total
photon emissions from the infected regions obtained for five mice. Data that differ significantly from those obtained at day 1 are shown (Student
t test, P 	 0.05). (C) Mean ( standard deviation) CFU recovered from granulomas at 1, 4, and 6 days postinfection. Data are expressed as
CFU/granuloma. Data at day 4 differ significantly from those obtained at day 1 (Student t test, P 	 0.05).
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albicans cells carrying the ACT1p-gLUC59 or control fusion
and imaged every day. As expected, luminescence was detected
in the kidney area for mice infected with the gLUC59-express-
ing strain. However, similar levels of luminescence were also
seen for the control strain and for mice that had not been
infected by C. albicans (data not shown). This suggested that
coelenterazine was unstable under these conditions, allowing
emission of light independently of any gLUC59 luciferase ac-
tivity. Moreover, when mice were injected with coelenterazine
and subsequently autopsied, light was not detected from the
kidney. Luminescence was detected only when the kidneys of
mice infected with the ACT1p-gLUC59 strain were homoge-
nized and incubated with coelenterazine (data not shown). As
expected, no significant luminescence was observed from the
homogenates from control kidneys. Therefore gLUC59 did not
appear to be a convenient reporter for imaging systemic C.
albicans infection.
DISCUSSION
In this study, we have developed a novel reporter gene for C.
albicans, i.e., PGA59-gLUC (also referred to as gLUC59). This
reporter takes advantage of the C. albicans PGA59 gene, which
encodes a GPI-linked cell wall protein (27), and the naturally
secreted G. princeps luciferase (44). This gLUC59 construction
was designed to localize the Pga59-gLUC protein to the C.
albicans cell surface. Characterization of C. albicans strains
expressing ACT1p-gLUC59, TRR1p-gLUC59, TRX1p-gLUC59,
IPF9996p-gLUC59, HWP1p-gLUC59, and EFT3p-gLUC59 fu-
sions under a variety of experimental conditions, including
morphogenetic and stress conditions, demonstrated the reli-
ability, versatility, and sensitivity of this novel reporter.
gLUC59 has significant advantages over the other luciferase
reporters that have been developed for gene expression studies
of C. albicans. gLUC59 is 300 times more sensitive than the
FIG. 6. In vivo imaging of mice infected cutaneously with Candida albicans ACT1p-gLUC59. Immunosuppressed mice were anesthesized and
shaved over an area of 4 cm2 until all fur was removed, and the skin was abraded with sandpaper until it glistened. A total of 107 ACT1p-gLUC59
(CA1398) or control (CA1399) cells in 20 l were deposited on the abraded area. Econazole and amphotericin B were administered intraperi-
toneally at a dose of 10 mg/kg of body weight once daily postinfection. Infection was monitored on days 1, 2, 3, 4, and 7 postinfection by depositing
10 g coelenterazine on the abraded skin area and imaging the animals dorsal side up in the IVIS-200 imaging system under anesthesia with 2.5%
isoflurane. (A) Representative images of mice infected with ACT1p-gLUC59 or control strains and treated with econazole or amphotericin B.
(B) Histogram of total photon emission from the infected regions observed in panel A.
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Renilla reniliformis luciferase (41) (Fig. 2). Cell lysates must be
prepared to assay expression of the Renilla reniliformis lucifer-
ase. In contrast, the cell surface exposure of gLUC59, and
hence its accessibility to its substrate coelenterazine, permits
direct measurement of expression levels through luciferase
assays on intact C. albicans cells (Fig. 2). Furthermore,
gLUC59 expression could be detected under all conditions
tested, including hyphal development (Fig. 3), a condition
where the firefly luciferase did not prove to be a convenient
reporter (8). In principle, given the sensitivity and ease of use
of gLUC59, this reporter could be exploited in a wide variety
of future applications. For example, gLUC59 could be used for
screening C. albicans mutants with altered gene expression or
for the detailed dissection of C. albicans promoter regions. In
this regard, we have shown that gLUC59 luciferase activity can
be effectively monitored on agar plates and in microtiter plate
assays (Fig. 2), thereby facilitating the implementation of high-
throughput screens based on differential gLUC59 expression
levels in C. albicans.
The primary aim of this study was to develop a reporter gene
for the imaging of C. albicans infections in vivo. We envisaged
that this reporter could be used to examine the spread of
infections, the efficacy of antifungal treatments, or the expres-
sion of infection-associated genes during disease progression.
Our results showed that a C. albicans strain expressing gLUC59
under the control of the constitutive ACT1 promoter could be
used to image subcutaneous and cutaneous infections (Fig. 5
and 6). This represents the first experimental examination of
such infections using imaging approaches. Cutaneous and sub-
cutaneous C. albicans infections are common dermatological con-
ditions that are exacerbated by several factors, including infancy,
pregnancy, old age, disorders of immunity, immunosuppressive
therapy, antibiotics, endocrine diseases, and carcinoma (18). In
certain subpopulations the prevalence of cutaneous candidiasis
has increased in recent years because the number of immuno-
compromised patients has increased (26). Our gLUC59 models of
cutaneous and subcutaneous Candida infection allow real-time
monitoring of yeast colonization. Importantly, the biolumines-
cence measurements correlated with yeast counts, suggesting that
the gLUC59 system provides an excellent tool for monitoring the
course of such infections as well as the efficacy of vaccine antigens
or pharmacological treatments. This is particularly relevant given
that local infections can be difficult to treat and may persist for
months, despite treatment.
FIG. 7. In vivo imaging of mice vaginally infected with Candida albicans ACT1p-gLUC59. (A) Mice under pseudo-estrus conditions were
infected for two consecutive days with 10 l of a 109-cell/ml suspension of ACT1p-gLUC59 (CA1398) or control (CA1399) cells into the vaginal
lumen. Starting on the first day postinfection and every day thereafter, mice were treated intravaginally with 10 g of coelenterazine and imaged
in the IVIS-200 imaging system under anesthesia with 2.5% isoflurane. (B) Representative example of the luciferase activity associated with the
vaginal lavage of mice infected for 5 days and whose vaginal lumens were thoroughly washed with 50 l of PBS using a mechanical pipette. The
lavage fluid was monitored with the IVIS-200 imaging system (insets). (C) Quantification of CFU (upper panel, mean  standard deviation) and
luciferase activity (lower panel, mean  standard deviation) in vaginal lavage fluid of two mice infected for 4, 5, 6, and 8 days.
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We also showed that the C. albicans ACT1p-gLUC59 strain
is an effective tool for the imaging of vaginal infections (Fig. 6).
Vulvovaginal candidiasis affects 75% of women at least once in
their reproductive years and is equally common in immuno-
competent and immunocompromised women (39, 40). It can
present as a chronic infection or have regular relapses. Recur-
rent or chronic vaginal candidiasis is a distressing problem for
women and an expensive issue for public health. The manage-
ment of these patients with recurrent vaginitis is a major chal-
lenge, and several studies are directed toward the development
of vaccination strategies and new antifungal drugs (25). The
ability to monitor yeast colonization in real time with a sensi-
tive reporter will significantly enhance the repertoire of tools
available for the analysis of vulvovaginal infections. This infec-
tion model has been studied using a luciferase-based imaging
system (8). However, that approach had limitations because it
was not able to reveal hyphal cells, thus underestimating the
extent of infection (8). In contrast, using gLUC59 we were able
to monitor both morphological forms of C. albicans in vulvo-
vaginal infections, thereby providing a more accurate model of
mucosal infection.
Despite repeated attempts, we were unable to image sys-
temic infections using C. albicans ACT1p-gLUC59 strains in
live animals. We obtained promising images of luminescence
emission from the kidney regions of live mice systemically
infected with these strains. However, similar images were ob-
tained for control mice infected with C. albicans strains lacking
gLUC59, probably through the autoluminescence of coelen-
terazine. In contrast, when autopsied animals were imaged,
only those infected with C. albicans ACT1p-gLUC59 strains
showed a significant luminescent signal in the kidney, the main
target organ of C. albicans upon systemic infection. Therefore,
current approaches for the live imaging of systemic C. albicans
infections with gLUC59 appear to be limited by the autolumi-
nescence of coelenterazine as well as by the uneven distribu-
tion of substrate throughout the mouse and the deep-seated
location of the kidneys, which precludes efficient visualization
of photons from this organ through the mouse body. The use
of stable coelenterazine derivatives such as ViviRen did not
overcome the problem of coelenterazine autoluminescence
(not shown), possibly because these derivatives require pro-
cessing by intracellular esterases in order to be used by lucif-
erases. In this regard, firefly luciferase uses luciferin, which is
intrinsically more stable than coelenterazine. Therefore, the
targeting of firefly luciferase to the C. albicans cell surface
using Pga59 signals might represent a suitable alternative to
gLUC59. Doyle et al. (8) have shown that intracellular firefly
luciferase in C. albicans does not permit in vivo imaging of
systemic C. albicans infections, possibly because of the limited
diffusion of luciferin across the cell walls/membranes of infect-
ing hyphae. Thus, the targeting of firefly luciferase to the C.
albicans cell surface might also provide a means of circumvent-
ing this limitation. However, firefly luciferase uses ATP for the
conversion of luciferin into light (37), and therefore the effi-
cient monitoring of firefly luciferase activity in vivo might be
limited by the availability of ATP in extracellular fluids.
Thus, future experiments should be aimed at improving the
mode of administration of coelenterazine and its stability in
vivo in order to take advantage of the exciting properties of
gLUC59 for the real-time monitoring of C. albicans infec-
tions in live animals. Meanwhile gLUC59 does provide a
sensitive tool for the analysis of systemic infections in au-
topsied animals.
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